Things have gone from bad to worse for Gemphire. Last month, the biotech cut a phase 2 fatty liver trial because some patients' disease got worse, and now it is cutting staff in a bid to cut costs and save cash.
Four days after Gemphire saw its shares $GEMP crushed by news of an FDA demand for additional safety data on its only drug before advancing it into Phase III, the biotech is back with more bad, terrible, absolutely no good news.
Less than a year after Gemphire shares $GEMP were doused by poor LDL numbers for its lead drug gemcabene, investors rallied to the cause with a fresh dose of positive Phase IIb results for the same therapy among patients with severe hypertriglyceridemia — or at least the way they defined the disease.